Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia
Michael J Binks, Sarah A Moberley, Anne Balloch, Amanda J Leach, Sandra Nelson, Kim M Hare, Cate Wilson, Jane Nelson, Peter S Morris, Robert S Ware, Mimi LK Tang, Paul J Torzillo, Jonathan R Carapetis, Kim Mulholland, Ross M Andrews
PNEUMONIA | GRIFFITH UNIV EPRESS | Published : 2018
Background: Indigenous children in Australia's Northern Territory are densely colonised with the pneumococcus within weeks of birth antecedent to a high prevalence of acute lower respiratory infection (ALRI). We assessed the impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in pregnancy against infant ALRI in this setting. Methods: In an open label, allocation concealed, outcome-assessor blinded, randomised controlled trial conducted in the Northern Territory of Australia, healthy Indigenous women aged 17-39 years were randomised to receive the 23vPPV during pregnancy (n = 75; 30-36 weeks gestation), at birth (n = 75), or at 7 months post-partum (n = 77). Randomisation was..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
This work was supported by the National Health and Medical Research Council of Australia (project grants 350499, 490320 and scholarship 1017225).